Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Postmenopausal Vaginal Atrophy Drugs Market by Therapy Type (Estrogen Based Drugs, Premarin, Vagifem, Estrace, Estring, Femring, Non Estrogen Based Drugs, BZA or CE, Osphena, Vaginorm) and by Drug Form (Vaginal Gels, Creams, Tablets, Rings, Patches): Global Opportunity Analysis and Industry Forecast, 2023-2032

A04029

Pages: NA

Charts: NA

Tables: NA

Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy. Symptoms of vaginal atrophy include redness, burning, itching, dyspareuia, and irritation. Diagnosis for PVA includes pelvic examination, vaginal smear test, vaginal activity test, blood test, and urine test.

Presence of favorable healthcare reforms, high unmet medical needs across emerging economies, and gradual shift from systemic estrogen treatments, such as vaginal gels, and patches, to non-estrogenic therapies drive the market. In addition, rise in prevalence of postmenopausal vaginal atrophy further accelerates the market growth. However, low diagnosis rate, and risk associated with the existing treatment options restricts the market. The advent of novel drugs with improved safety are expected to tap the unmet needs and provide lucrative market growth opportunities.

The report segments the global PVA market based on therapy type and drug forms. Based on therapy type, the market is categorized into estrogen-based drugs (Premarin, Vagifem, Estrace, Estring and Femring) and non-estrogen-based drugs (BZA/CE, Osphena, and Vaginorm). Based on drug forms, the market is categorized as vaginal gels, creams, tablets, rings, and patches. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in the global PVA market include Actavis plc, Bionovo, Inc., Endoceutics, Inc., Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Ltd., Therapeutics MD, Inc., Shionogi & Company, Limited, Allergan plc, and Shionogi & Co. Ltd.

Key Benefits

  • The study provides an in-depth analysis of the global PVA market and the current trends and future estimations to elucidate the imminent investment pockets.
  • The report presents quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on product assists to understand the trends in the industry.
  • Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

 Key Market Segments

  • By Therapy Type
    • Estrogen Based Drugs
    • Premarin
    • Vagifem
    • Estrace
    • Estring
    • Femring
    • Non Estrogen Based Drugs
    • BZA or CE
    • Osphena
    • Vaginorm
  • By Drug Form
    • Vaginal Gels
    • Creams
    • Tablets
    • Rings
    • Patches
  • By Region
    • North America
    • Europe
    • Asia-Pacific
    • LAMEA

 
Key Market Players

  • Pfizer Inc.
  • Novo Nordisk AS
  • Allergan plc
  • Shionogi and Co. Ltd
  • Bionovo, Inc.
  • Endoceutics, Inc.
  • Therapeutics MD, Inc.
  • Actavis plc
  • Teva Pharmaceuticals Ltd.
  • Shionogi and Company, Limited

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET, BY THERAPY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapy Type

    • 4.2. Estrogen Based Drugs

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Premarin

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Vagifem

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Estrace

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Estring

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Femring

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Non Estrogen Based Drugs

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. BZA Or CE

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

    • 4.10. Osphena

      • 4.10.1. Key Market Trends, Growth Factors and Opportunities

      • 4.10.2. Market Size and Forecast, By Region

      • 4.10.3. Market Share Analysis, By Country

    • 4.11. Vaginorm

      • 4.11.1. Key Market Trends, Growth Factors and Opportunities

      • 4.11.2. Market Size and Forecast, By Region

      • 4.11.3. Market Share Analysis, By Country

  • CHAPTER 5: POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET, BY DRUG FORM

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Drug Form

    • 5.2. Vaginal Gels

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Creams

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Tablets

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Rings

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Patches

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Therapy Type

      • 6.2.3. Market Size and Forecast, By Drug Form

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Postmenopausal Vaginal Atrophy Drugs Market

        • 6.2.5.1. Market Size and Forecast, By Therapy Type
        • 6.2.5.2. Market Size and Forecast, By Drug Form

      • 6.2.6. Canada Postmenopausal Vaginal Atrophy Drugs Market

        • 6.2.6.1. Market Size and Forecast, By Therapy Type
        • 6.2.6.2. Market Size and Forecast, By Drug Form

      • 6.2.7. Mexico Postmenopausal Vaginal Atrophy Drugs Market

        • 6.2.7.1. Market Size and Forecast, By Therapy Type
        • 6.2.7.2. Market Size and Forecast, By Drug Form

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Therapy Type

      • 6.3.3. Market Size and Forecast, By Drug Form

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Postmenopausal Vaginal Atrophy Drugs Market

        • 6.3.5.1. Market Size and Forecast, By Therapy Type
        • 6.3.5.2. Market Size and Forecast, By Drug Form

      • 6.3.6. Germany Postmenopausal Vaginal Atrophy Drugs Market

        • 6.3.6.1. Market Size and Forecast, By Therapy Type
        • 6.3.6.2. Market Size and Forecast, By Drug Form

      • 6.3.7. Italy Postmenopausal Vaginal Atrophy Drugs Market

        • 6.3.7.1. Market Size and Forecast, By Therapy Type
        • 6.3.7.2. Market Size and Forecast, By Drug Form

      • 6.3.8. Spain Postmenopausal Vaginal Atrophy Drugs Market

        • 6.3.8.1. Market Size and Forecast, By Therapy Type
        • 6.3.8.2. Market Size and Forecast, By Drug Form

      • 6.3.9. UK Postmenopausal Vaginal Atrophy Drugs Market

        • 6.3.9.1. Market Size and Forecast, By Therapy Type
        • 6.3.9.2. Market Size and Forecast, By Drug Form

      • 6.3.10. Russia Postmenopausal Vaginal Atrophy Drugs Market

        • 6.3.10.1. Market Size and Forecast, By Therapy Type
        • 6.3.10.2. Market Size and Forecast, By Drug Form

      • 6.3.11. Rest Of Europe Postmenopausal Vaginal Atrophy Drugs Market

        • 6.3.11.1. Market Size and Forecast, By Therapy Type
        • 6.3.11.2. Market Size and Forecast, By Drug Form

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Therapy Type

      • 6.4.3. Market Size and Forecast, By Drug Form

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Postmenopausal Vaginal Atrophy Drugs Market

        • 6.4.5.1. Market Size and Forecast, By Therapy Type
        • 6.4.5.2. Market Size and Forecast, By Drug Form

      • 6.4.6. Japan Postmenopausal Vaginal Atrophy Drugs Market

        • 6.4.6.1. Market Size and Forecast, By Therapy Type
        • 6.4.6.2. Market Size and Forecast, By Drug Form

      • 6.4.7. India Postmenopausal Vaginal Atrophy Drugs Market

        • 6.4.7.1. Market Size and Forecast, By Therapy Type
        • 6.4.7.2. Market Size and Forecast, By Drug Form

      • 6.4.8. South Korea Postmenopausal Vaginal Atrophy Drugs Market

        • 6.4.8.1. Market Size and Forecast, By Therapy Type
        • 6.4.8.2. Market Size and Forecast, By Drug Form

      • 6.4.9. Australia Postmenopausal Vaginal Atrophy Drugs Market

        • 6.4.9.1. Market Size and Forecast, By Therapy Type
        • 6.4.9.2. Market Size and Forecast, By Drug Form

      • 6.4.10. Thailand Postmenopausal Vaginal Atrophy Drugs Market

        • 6.4.10.1. Market Size and Forecast, By Therapy Type
        • 6.4.10.2. Market Size and Forecast, By Drug Form

      • 6.4.11. Malaysia Postmenopausal Vaginal Atrophy Drugs Market

        • 6.4.11.1. Market Size and Forecast, By Therapy Type
        • 6.4.11.2. Market Size and Forecast, By Drug Form

      • 6.4.12. Indonesia Postmenopausal Vaginal Atrophy Drugs Market

        • 6.4.12.1. Market Size and Forecast, By Therapy Type
        • 6.4.12.2. Market Size and Forecast, By Drug Form

      • 6.4.13. Rest of Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market

        • 6.4.13.1. Market Size and Forecast, By Therapy Type
        • 6.4.13.2. Market Size and Forecast, By Drug Form

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Therapy Type

      • 6.5.3. Market Size and Forecast, By Drug Form

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Postmenopausal Vaginal Atrophy Drugs Market

        • 6.5.5.1. Market Size and Forecast, By Therapy Type
        • 6.5.5.2. Market Size and Forecast, By Drug Form

      • 6.5.6. South Africa Postmenopausal Vaginal Atrophy Drugs Market

        • 6.5.6.1. Market Size and Forecast, By Therapy Type
        • 6.5.6.2. Market Size and Forecast, By Drug Form

      • 6.5.7. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Market

        • 6.5.7.1. Market Size and Forecast, By Therapy Type
        • 6.5.7.2. Market Size and Forecast, By Drug Form

      • 6.5.8. UAE Postmenopausal Vaginal Atrophy Drugs Market

        • 6.5.8.1. Market Size and Forecast, By Therapy Type
        • 6.5.8.2. Market Size and Forecast, By Drug Form

      • 6.5.9. Argentina Postmenopausal Vaginal Atrophy Drugs Market

        • 6.5.9.1. Market Size and Forecast, By Therapy Type
        • 6.5.9.2. Market Size and Forecast, By Drug Form

      • 6.5.10. Rest of LAMEA Postmenopausal Vaginal Atrophy Drugs Market

        • 6.5.10.1. Market Size and Forecast, By Therapy Type
        • 6.5.10.2. Market Size and Forecast, By Drug Form

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Actavis Plc

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Bionovo, Inc.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Endoceutics, Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Novo Nordisk AS

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Pfizer Inc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Teva Pharmaceuticals Ltd.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Therapeutics MD, Inc.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Shionogi And Company, Limited

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Allergan Plc

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Shionogi And Co. Ltd

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR ESTROGEN BASED DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR PREMARIN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR VAGIFEM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR ESTRACE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR ESTRING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR FEMRING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR NON ESTROGEN BASED DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR BZA OR CE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR OSPHENA, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR VAGINORM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR VAGINAL GELS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR CREAMS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR TABLETS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR RINGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR PATCHES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. NORTH AMERICA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. NORTH AMERICA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 22. U.S. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. U.S. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 24. CANADA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 25. CANADA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 31. FRANCE POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 33. GERMANY POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 34. GERMANY POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 35. ITALY POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 36. ITALY POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 37. SPAIN POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. SPAIN POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 39. UK POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. UK POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 41. RUSSIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 42. RUSSIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 43. REST OF EUROPE POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 44. REST OF EUROPE POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 45. ASIA-PACIFIC POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 46. ASIA-PACIFIC POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 47. ASIA-PACIFIC POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 48. CHINA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 49. CHINA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 50. JAPAN POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 51. JAPAN POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 52. INDIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 53. INDIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 54. SOUTH KOREA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 55. SOUTH KOREA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 56. AUSTRALIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 57. AUSTRALIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 58. THAILAND POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. THAILAND POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 60. MALAYSIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. MALAYSIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 62. INDONESIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 63. INDONESIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 64. REST OF ASIA PACIFIC POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 65. REST OF ASIA PACIFIC POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 66. LAMEA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 67. LAMEA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 68. LAMEA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 69. BRAZIL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 70. BRAZIL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 71. SOUTH AFRICA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 72. SOUTH AFRICA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 73. SAUDI ARABIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 74. SAUDI ARABIA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 75. UAE POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 76. UAE POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 77. ARGENTINA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 78. ARGENTINA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 79. REST OF LAMEA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY THERAPY TYPE, 2025-2033 ($MILLION)
  • TABLE 80. REST OF LAMEA POSTMENOPAUSAL VAGINAL ATROPHY DRUGS, BY DRUG FORM, 2025-2033 ($MILLION)
  • TABLE 81. ACTAVIS PLC: KEY EXECUTIVES
  • TABLE 82. ACTAVIS PLC: COMPANY SNAPSHOT
  • TABLE 83. ACTAVIS PLC: OPERATING SEGMENTS
  • TABLE 84. ACTAVIS PLC: PRODUCT PORTFOLIO
  • TABLE 85. ACTAVIS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. BIONOVO, INC.: KEY EXECUTIVES
  • TABLE 87. BIONOVO, INC.: COMPANY SNAPSHOT
  • TABLE 88. BIONOVO, INC.: OPERATING SEGMENTS
  • TABLE 89. BIONOVO, INC.: PRODUCT PORTFOLIO
  • TABLE 90. BIONOVO, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. ENDOCEUTICS, INC.: KEY EXECUTIVES
  • TABLE 92. ENDOCEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 93. ENDOCEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 94. ENDOCEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 95. ENDOCEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. NOVO NORDISK AS: KEY EXECUTIVES
  • TABLE 97. NOVO NORDISK AS: COMPANY SNAPSHOT
  • TABLE 98. NOVO NORDISK AS: OPERATING SEGMENTS
  • TABLE 99. NOVO NORDISK AS: PRODUCT PORTFOLIO
  • TABLE 100. NOVO NORDISK AS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. PFIZER INC.: KEY EXECUTIVES
  • TABLE 102. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 103. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 104. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 105. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. TEVA PHARMACEUTICALS LTD.: KEY EXECUTIVES
  • TABLE 107. TEVA PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
  • TABLE 108. TEVA PHARMACEUTICALS LTD.: OPERATING SEGMENTS
  • TABLE 109. TEVA PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
  • TABLE 110. TEVA PHARMACEUTICALS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. THERAPEUTICS MD, INC.: KEY EXECUTIVES
  • TABLE 112. THERAPEUTICS MD, INC.: COMPANY SNAPSHOT
  • TABLE 113. THERAPEUTICS MD, INC.: OPERATING SEGMENTS
  • TABLE 114. THERAPEUTICS MD, INC.: PRODUCT PORTFOLIO
  • TABLE 115. THERAPEUTICS MD, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. SHIONOGI AND COMPANY, LIMITED: KEY EXECUTIVES
  • TABLE 117. SHIONOGI AND COMPANY, LIMITED: COMPANY SNAPSHOT
  • TABLE 118. SHIONOGI AND COMPANY, LIMITED: OPERATING SEGMENTS
  • TABLE 119. SHIONOGI AND COMPANY, LIMITED: PRODUCT PORTFOLIO
  • TABLE 120. SHIONOGI AND COMPANY, LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. ALLERGAN PLC: KEY EXECUTIVES
  • TABLE 122. ALLERGAN PLC: COMPANY SNAPSHOT
  • TABLE 123. ALLERGAN PLC: OPERATING SEGMENTS
  • TABLE 124. ALLERGAN PLC: PRODUCT PORTFOLIO
  • TABLE 125. ALLERGAN PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. SHIONOGI AND CO. LTD: KEY EXECUTIVES
  • TABLE 127. SHIONOGI AND CO. LTD: COMPANY SNAPSHOT
  • TABLE 128. SHIONOGI AND CO. LTD: OPERATING SEGMENTS
  • TABLE 129. SHIONOGI AND CO. LTD: PRODUCT PORTFOLIO
  • TABLE 130. SHIONOGI AND CO. LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET
  • FIGURE 3. SEGMENTATION POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPOSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET
  • FIGURE 11. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET SEGMENTATION, BY BY THERAPY TYPE
  • FIGURE 12. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR ESTROGEN BASED DRUGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR PREMARIN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR VAGIFEM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR ESTRACE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR ESTRING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR FEMRING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR NON ESTROGEN BASED DRUGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR BZA OR CE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR OSPHENA, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR VAGINORM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET SEGMENTATION, BY BY DRUG FORM
  • FIGURE 23. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR VAGINAL GELS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR CREAMS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR TABLETS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR RINGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET FOR PATCHES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 29. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 30. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 31. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 32. COMPETITIVE DASHBOARD
  • FIGURE 33. COMPETITIVE HEATMAP: POSTMENOPAUSAL VAGINAL ATROPHY DRUGS MARKET
  • FIGURE 34. TOP PLAYER POSITIONING, 2024
  • FIGURE 35. ACTAVIS PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. ACTAVIS PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. ACTAVIS PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. BIONOVO, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. BIONOVO, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. BIONOVO, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. ENDOCEUTICS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. ENDOCEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. ENDOCEUTICS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. NOVO NORDISK AS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. NOVO NORDISK AS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. NOVO NORDISK AS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. PFIZER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. PFIZER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 50. TEVA PHARMACEUTICALS LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 51. TEVA PHARMACEUTICALS LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 52. TEVA PHARMACEUTICALS LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 53. THERAPEUTICS MD, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 54. THERAPEUTICS MD, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 55. THERAPEUTICS MD, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 56. SHIONOGI AND COMPANY, LIMITED: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 57. SHIONOGI AND COMPANY, LIMITED: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 58. SHIONOGI AND COMPANY, LIMITED: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 59. ALLERGAN PLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 60. ALLERGAN PLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 61. ALLERGAN PLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 62. SHIONOGI AND CO. LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 63. SHIONOGI AND CO. LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 64. SHIONOGI AND CO. LTD: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Postmenopausal Vaginal Atrophy Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved